Conformationally restricted homotryptamines. Part 5: 3-(trans-2-aminomethylcyclopentyl)indoles as potent selective serotonin reuptake inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 15, 2009, Pages 4031-4033

  Denhart, Derek J ^a   Deskus, Jeffrey A ^a   Ditta, Jonathan L ^a   Gao, Qi ^a   Dalton King, H ^a   Kozlowski, Edward S ^a   Meng, Zhaoxing ^a   LaPaglia, Melissa A ^a   Mattson, Gail K ^a   Molski, Thaddeus F ^a   Taber, Matthew T ^a   Lodge, Nicholas J ^a   Mattson, Ronald J ^a   Macor, John E ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Homotryptamines; Indoles; Serotonin; SSRI

Indexed keywords

3 (2 AMINOMETHYLCYCLOPENTYL)INDOLE DERIVATIVE; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CONFORMATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENANTIOMER; IC 50; IN VIVO STUDY; NONHUMAN; RAT; STEREOCHEMISTRY; STEREOISOMERISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; CHEMISTRY, PHARMACEUTICAL; CYCLOPENTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; LIGANDS; MODELS, CHEMICAL; PROTEIN BINDING; RATS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTAMINES;

EID: 67649959169     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.06.026     Document Type: Article

References (17)

1. Spinks D., and Spinks G. Curr. Med. Chem. 9 (2002) 799
2. Ananth J. Psychother. Psychosom. 67 (1998) 61
3. Rocco V.P., Spinazze P.G., Kohn T.J., Honigschmidt N.A., Nelson D.L., Wainscott D.B., Ahmad L.J., Shaw J., Threlkeld P.G., Wong D.T., and Takeguchi K. Bioorg. Med. Chem. Lett. 14 (2004) 2653
4. Oficialdegui A.M., Martinez J., Perez S., Hears B., Irurzun M., Palop J.A., Tordera R., Lasheras B., del Rio J., and Monge A. Farmaco 55 (2000) 345
5. Evrard D.A., Zhou P., Yi S., Zhow D., Smith D., Sullivan K.M., Hornby G.A., Scheckter L.E., Andree T.H., and Mewshaw R.E. Bioorg. Med. Chem. Lett. 15 (2005) 911
6. Ryckmans T., Balancon L., Berton O., Genicot C., Lamberty Y., Lallemand B., Pasau P., Pirol N., Quere L., and Talaga P. Bioorg. Med. Chem. Lett. 12 (2002) 261
7. Ryckmans T., Berton O., Grimee R., Kogej T., Lamberty Y., Pasau P., Talaga P., and Genicot C. Bioorg. Med. Chem. Lett. 12 (2002) 3195
8. Schmitz W.D., Denhart D.J., Brenner A.B., Ditta J.L., Mattson R.J., Mattson G.K., Molski T.F., and Macor J.E. Bioorg. Med. Chem. Lett. 15 (2005) 1619
9. Denhart D.J., Mattson R.J., Ditta J.L., and Macor J.E. Tetrahedrom Lett. 45 (2004) 3803
10. Deskus J.A., Epperson J.R., Sloan C.P., Cipollina J.A., Dextraze P., Qian-Cutrone J., Gao Q., Ma B., Beno B.R., Mattson G.K., Molski T.F., Krause R.G., Taber M.T., Lodge N.J., and Mattson R.J. Bioorg. Med. Chem. Lett. 17 (2007) 3099
11. Mattson R.J., Catt J.D., Denhart D.J., Deskus J.A., Ditta J.L., Higgins M.A., Marcin L.R., Sloan C.P., Beno B.R., Gao Q., Cunningham M.A., Mattson G.K., Molski T.F., Taber M.T., and Lodge N.J. J. Med. Chem. 48 (2005) 6023
12. Ciattini P.G., Morera E., and Ortar G. Tetrahedron Lett. 35 (1994) 2405
13. 50 in nM) signified the potency.
14. King H.D., Meng Z., Denhart D., Mattson R., Kimura R., Wu D., Gao Q., and Macor J.E. Org. Lett. 7 (2005) 3437
15. Omura K., and Swern D. Tetrahedron Lett. 34 (1978) 1651
16. 50 data was determined from a 20-point curve. Non-specific binding was defined using 10 μM fluoxetine for SERT, 100 μM Desipramine for NET, and 10 μM GBR-12935 for DAT.
17. Taber M.T., Wright R.N., Molski T.F., Clarke W.J., Brassil P.J., Denhart D.J., Mattson R.J., and Lodge N.J. Pharmacol., Biochem. Behav. 80 (2005) 521